Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($) |
3 Months Ended | 6 Months Ended | ||
|---|---|---|---|---|
Jun. 30, 2023 |
Jun. 30, 2022 |
Jun. 30, 2023 |
Jun. 30, 2022 |
|
| Revenue from Contract with Customer [Abstract] | ||||
| Product Revenue | ||||
| Product Cost of Sales | ||||
| Gross Income | ||||
| Administrative Expenses | 1,879,917 | 1,346,763 | 2,867,904 | 2,741,875 |
| Research and Development Expenses | 2,224,444 | 2,163,968 | 2,994,874 | 4,793,711 |
| Stock Based Compensation Expenses | 1,677,271 | 132,246 | 1,746,339 | 229,245 |
| Warrant Issuance Expenses | 762,834 | |||
| Loss from Operations | (5,781,632) | (3,642,977) | (8,371,951) | (7,764,831) |
| Other (Income) Expenses | ||||
| Interest and Dividend Income | (174,851) | (5,986) | (200,675) | (6,106) |
| (Gain)/Loss on Sale of Marketable Securities | 389 | 1,999 | 214 | 3,649 |
| Change in fair value of Marketable Securities | 983 | (2,947) | 2,695 | 145 |
| Change in fair value of Derivatives Liabilities | 1,490,200 | 315,200 | ||
| Change in fair value of Warrant Liabilities | (2,930,700) | (2,810,000) | ||
| Uninsured Casualty Loss | (4,442) | |||
| Total Other Income | (1,613,979) | (6,934) | (2,692,566) | (6,754) |
| Loss Before Income Tax | (4,167,653) | (3,636,043) | (5,679,385) | (7,758,077) |
| Income Tax Benefit | ||||
| Net Loss | (4,167,653) | (3,636,043) | (5,679,385) | (7,758,077) |
| Preferred Stock Dividends | 373,796 | 532,129 | ||
| Net Loss Attributable to Common Stockholders | $ (4,541,449) | $ (3,636,043) | $ (6,211,514) | $ (7,758,077) |
| Basic loss per common share | $ (0.11) | $ (0.09) | $ (0.16) | $ (0.20) |
| Diluted loss per common share | $ (0.11) | $ (0.09) | $ (0.16) | $ (0.20) |
| Weighted average basic common shares outstanding | 40,351,806 | 38,325,311 | 40,071,084 | 38,224,679 |
| Weighted average diluted common shares outstanding | 40,351,806 | 38,325,311 | 40,071,084 | 38,224,679 |
| X | ||||||||||
- Definition Gain (Losses) on fair value of derivative liability. No definition available.
|
| X | ||||||||||
- Definition Uninsured Casualty Losses. No definition available.
|
| X | ||||||||||
- Definition Warrant issuance expenses. No definition available.
|
| X | ||||||||||
- Definition The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of expense (income) related to adjustment to fair value of warrant liability. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount before accretion (amortization) of purchase discount (premium) of interest income and dividend income on nonoperating securities. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of realized gain (loss) on investment in marketable security, including other-than-temporary impairment (OTTI). No definition available.
|
| X | ||||||||||
- Definition Amount of unrealized gain (loss) on investment in marketable security. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business). Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The net result for the period of deducting operating expenses from operating revenues. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The aggregate value of preferred stock dividends and other adjustments necessary to derive net income apportioned to common stockholders. Reference 1: http://www.xbrl.org/2003/role/recommendedDisclosureRef
|
| X | ||||||||||
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of noncash expense for share-based payment arrangement. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|